NCT04536337View on ClinicalTrials.gov

A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

October 22, 2020

Primary Completion Date

June 16, 2025

Study Completion Date

June 16, 2025

Conditions
Chronic Hepatitis B
Interventions
DRUG

ALG-000184

Single or multiple doses of ALG-000184

DRUG

Placebo

Single or multiple doses of Placebo

DRUG

Entecavir

multiple doses of Entecavir

Trial Locations (10)

3011

Western Health, Footscray

3065

Saint Vincent's Hospital Melbourne, Fitzroy

72218

CAP Research, Quatre Bornes

130021

The First Hospital of Jilin University, Changchun

400016

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

Unknown

Nanfang Hospital of Southern Medical University, Guangzhou

Queen Mary Hospital, Hong Kong

Prince of Wales, Shatin

"PMSI Republican Clinical Hospital T. Mosneaga, ARENSIA Exploratory Medicine Phase I Unit", Chisinau

ACS, Auckland

Sponsors
All Listed Sponsors
lead

Aligos Therapeutics

INDUSTRY

NCT04536337 - A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects | Biotech Hunter | Biotech Hunter